SEC Form 4 · accession 0001636050-17-000021
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
W Anthony Vernon
Director
Period of report
May 15, 2017
Accepted (ET)
May 16, 2017 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $21.90 | May 15, 2017 | A | 70,000 | A | — | May 14, 2027 | Common Shares | 70,000 | 70,000 | D |
Explanation of responses
- F1This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.